Doya Medical
Nonsurgical Treatment for Otitis Media with Effusion
Company Overview
Snapshot
Founded in May 2015 by Galit Avior and Shenfeld Inbal, Doya Medical operated with 1–10 employees. The company secured $1.5M in total capital raised across one funding round. A key development was its acceptance into the MassChallenge accelerator in London, which provided support for international market entry.
Business overview
Doya Medical specializes in developing noninvasive e-stent technology to treat otitis media with effusion, aiming to reduce or eliminate the need for traditional ear tube surgery. The company's core product is an active stent designed to naturally drain fluid from the ear, accompanied by an optically guided delivery system for eustachian tube insertion. This technology targets the healthcare market, specifically medical device and treatment sectors, serving healthcare providers and patients by improving quality of life, reducing recovery times, and lowering medical costs.
Log in to access full profile ›Company Intelligence Q&A
- What is Doya Medical's primary focus?
- Doya Medical focuses on developing a noninvasive e-stent technology for the treatment of otitis media with effusion, aiming to provide an alternative to ear tube surgery.
- Who founded Doya Medical?
- Doya Medical was founded by Galit Avior and Shenfeld Inbal in May 2015.
- What was a significant early achievement for Doya Medical?
- Doya Medical was a silver winner in the MassChallenge global start-up competition in 2015.
- What is the status of Doya Medical?
- Doya Medical ceased to operate in September 2020.
- What was the total capital raised by Doya Medical?
- Doya Medical raised $1.5M in total capital.